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Abstract
● AIM: To evaluate the therapeutic efficacy, safety 
and tolerability of newly developed preservative-free 
(PF) latanoprost generic [TJO-002] and compare it with 
benzalkonium chloride (BAK)-preserved latanoprost 
[Xalatan®] in patients with primary open angle glaucoma 
(POAG) and ocular hypertension (OHT).
● METHODS: Included patients were aged ≥19y with 
POAG/OHT. After a washout period, patients with IOP 21-
35 mm Hg at 9 a.m. were enrolled. After a full ophthalmic 
and glaucoma examination, 144 patients with POAG and 
OHT participated in this study. Subjects were randomly 
assigned either PF latanoprost (74 eyes) or BAK-preserved 
latanoprost (70 eyes). All subjects were examined at 4, 8, 
and 12wk after first administration. At each follow-up visit, 
IOP was measured at 9 a.m. and 5 p.m. and compliance 
was assessed. Throughout the study, all adverse events 
were recorded and monitored by the masked investigators 
who measured IOP.
● RESULTS: Both groups showed a statistically significant 
decrease of average diurnal IOP at 12wk compared to 
baseline (-7.21±3.10 mm Hg in the PF latanoprost group 
and -7.02±3.17 mm Hg in the BAK latanoprost group, both 
P<0.0001). There was no statistically significant diurnal 
IOP variation between the groups. In terms of tolerability, 
pruritus, burning/stinging, and sticky eye sensation, severity 
was significantly lower in the PF latanoprost group than in 
the BAK latanoprost group (P<0.05). 
● CONCLUSION: PF latanoprost has at least similar 
efficacy in terms of IOP reduction and better tolerability 
compared with BAK latanoprost. 
● KEYWORDS: latanoprost; benzalkonium chloride; 
intraocular pressure; preservative-free; 
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INTRODUCTION 
G laucoma is a major cause of irreversible blindness worldwide, and 111.8 million patients are expected 
globally by 2040[1]. Although many factors have been suggested 
as causes of glaucoma development, intraocular pressure (IOP) 
is still thought to be a major factor in the development and 
progression of glaucoma[2-3]. Many studies have reported that 
treatments that lower IOP decrease glaucoma progression[4-8]. 
To date, control of IOP is the only proven way to suppress the 
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progression of glaucoma. Therefore, IOP reduction remains the 
cornerstone of glaucoma management[9].
Prostaglandin analogue (PGA) has been used more and more 
frequently as it is preferred as a first-time glaucoma drug, 
which is effective and has less severe systemic side effects and 
requires only one dose per day[10]. Among the various PGAs, 
latanoprost, which was first developed, is the most widely 
used in ocular hypertension (OHT) and primary open angle 
glaucoma (POAG) due to its good effect and less side effects 
such as conjunctival hyperemia compared to other PGAs[10-12]. 
However, latanoprost eye drops currently commonly used 
have a high concentration of benzalkonium chloride (BAK) 
and contain sodium phosphate, which could cause side effects 
such as conjunctivitis and corneal surface epithelial toxicity 
when administered for a long time[13-14]. Ocular surface changes 
that occur using prostaglandin eye drops with BAK can be 
significantly related to the concentration-dependent cytotoxicity 
of these preservatives[15]. In addition, the side effects of BAK 
may have a greater impact on glaucoma patients who need to 
use their medicine for life. On the other hand, in the case of 
preservative-free (PF) latanoprost, few apoptosis cells were 
found in the superficial layer of the corneal epithelium in 
human and toxic animal models[15-16]. Therefore, in the 2009 
EMA guideline, the European Glaucoma Society recommends 
PF products for patients with glaucoma who have dry eye or 
ocular surface diseases[17]. 
Recently, a PF latanoprost generic eye drop was developed, 
TJO-002 (Xalost® S in Korea). TJO-002 has been formulated 
to have several presumed advantages over the conventional 
latanoprost preparation, which contains BAK. Polyoxyl 40 
hydrogenated castor oil, carbomer (mucoadhesive polymer), 
and high-concentration sorbitol were used to promote substance 
stabilization and penetration into the eyeball instead of BAK 
and sodium phosphate. In order to improve the tolerability, 
instead of having a pH of 5.5 like the conventional latanoprost 
formulation [Xalatan®], TJO-002 has a physiologically active 
pH range of 7.0-7.3. This new formulation focuses on high 
stability, tolerability and non-inferior efficacy compared with 
the conventional formulation. This study aimed to compare 
TJO-002 with BAK-preserved latanoprost for IOP-lowering 
efficacy, safety and tolerability in patients with POAG/OHT.
SUBJECTS AND METHODS
Ethical Approval  This study was approved by the Institutional 
Review Board of each center. This study was performed 
according to the tenets of the Helsinki Declaration 
and compliance with the International Conference on 
Harmonization Good Clinical Practice guidelines and Korean 
regulations. All patients were fully informed and provided 
written consent for participation before enrollment. 
Study Design and Patients  The study was a multicenter, 
randomized, investigator-masked, active control, and parallel-
group phase III clinical trial (NCT03419975). It was conducted 
in 17 clinical sites from 3 December 2015 to 5 March 2018. 
This study compared the newly developed PF latanoprost 
formulation TJO-002 (Taejoon Pharmaceutical Co., Ltd., 
Yongin, Republic of Korea) with BAK-preserved latanoprost 
(Xalatan®, Pfizer Inc., Belgium NV Puurs, Belgium) during 
a 3-month treatment period. Given that TJO-002 is supplied 
in single dose units and BAK latanoprost in bottles, the 
investigational drug was managed by dividing the blind part 
and the unblind part and the investigator was blind part so that 
they could not know which eyedrop to be administered, only 
the investigator measuring IOP during the ophthalmological 
examination was masked to the study medication.
This study enrolled adult patients (≥19 years of age) with 
POAG/OHT. Patients with an IOP of 21 to 35 mm Hg at 9 a.m. 
(±1h) in eligible eyes after a run-in period were randomized 
1:1 and assigned the treatment schedule with TJO-002 or 
BAK latanoprost administered as one drop daily in each eye. 
We excluded the patients who had 20/80 or below of best-
corrected visual acuity on the Snellen chart and medical 
history of chronic intraocular inflammation in progress or 
within 3mo prior to screening. Patients who needed to use 
contact lenses during the clinical study and women who were 
pregnant, planning to become pregnant, currently nursing, 
of childbearing potential, or not using a reliable form of 
contraception were also excluded. Patients were randomized 
if IOP was >21 mm Hg in the eligible eye(s). If both eyes 
met the criteria, the eye with the higher IOP was selected. If 
the IOP was equal, the right eye was selected. Patients were 
instructed to instill one drop in each eye once daily in the evening 
(9 p.m. ±1h) and were scheduled for follow-up visits at 4, 8, 
and 12wk. The subjects were asked to keep a daily indication 
of whether or not to take an investigational drug in their diary 
table every time they administered, and were asked to answer 
the symptoms that they felt bad for the last week before the visit.
Assessment Parameters  The primary efficacy variable was 
the change in IOP between baseline and 12wk in the study eye. 
Diurnal IOP (average of 2 consecutive IOP measurements) 
was measured at the same hour (9 a.m. ±1h and 5 p.m. ±1h) 
at each visit using a calibrated Goldmann applanation tonometer 
(Figure 1). All patients underwent ocular examinations, including 
visual acuity assessment, slit lamp biomicroscopy, gonioscopy, 
standard automated perimetry, and ophthalmoscopy. IOP 
was measured (at 9 a.m. and 5 p.m.) during the baseline 
visit and at the 8-week and 12-week visits after eye-drop 
instillation. At the 4-week visit after instillation, IOP was 
measured only at 9 a.m. Safety outcome measures included 
adverse events (AEs) reporting, visual acuity, and tolerability. 
Preservative-free latanoprost
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Tolerability was evaluated with the frequency and percentage 
of distributions of severity level by symptoms in each group 
after administration at 4, 8, and 12wk with questionnaire in 
the blind part (investigator). The symptoms checked during 
follow-up visits were pruritus, burning/stinging, blurred vision, 
sticky eye sensation, eye dryness sensation, and foreign body 
sensation. Each of symptoms was written by investigator about 
the symptoms subjects feel after instilling investigational 
drugs. The tolerability was evaluated by checking how the 
symptoms were changed based on the symptoms of the worst 
degree among the records written about the symptoms of the 
investigational drug administration for a week before visit.
Statistical Analysis  The primary objective was to demonstrate 
the non-inferiority of the trial drug to the control drug in 
terms of diurnal IOP variation after the administration of 
the drugs for 12wk. If the maximum value of the confidence 
intervals was less than 1.5 mm Hg, the trial group was judged 
to be non-inferior to the control group[18]. The upper limit of 
noninferiority was set at 1.5 mm Hg as this is the standard 
acceptance level for noninferiority in glaucoma studies[19-21]. 
The adjusted average and standard error of the IOP variations 
in the trial and control groups, the difference between the 
average and adjusted average, 95% two-tailed confidence 
intervals of adjusted average difference and P-values 
were calculated by conducting an analysis of covariation 
(ANCOVA) with baseline IOP as covariate and treatment as a 
parameter for IOP variations. Additionally, if there were any 
statistically significant variables among sex, ages, and BMI 
distribution, an ANCOVA was performed that corrected for 
these variables as a sensitivity analysis. Statistical analyses 
were performed using SAS v9.2 (SAS Institute, Cary, NC, 
USA). Tolerability was evaluated with the frequency and 
percentage of severity level distribution for each symptom in 
each group at 4, 8, and 12wk, and those differences between 
the groups were evaluated through Chi-square tests or 
Fisher’s exact tests. When there was a missing value, the last 
observation carried forward method was used. 
RESULTS 
Among 196 consenting subjects, 52 people were excluded 
(38 patients with “Deviation of inclusion/exclusion criteria”, 
13 with “Consent withdrawal” and 1 with “Other”), and 144 
people were randomized. The full description of the inclusion 
and exclusion steps is outlined in Figure 2.
Demographic Characteristics  There were 78.38% men vs 
21.62% women in the TJO-002 group and 60.00% men vs 
40.00% women in the BAK latanoprost group. The sex ratios 
between the two groups were statistically significantly different 
(P=0.0167). There were no differences in other characteristics 
between the two groups (P>0.05; Table 1).
Efficacy  Twelve weeks after initiation of drug administration, 
the mean diurnal IOP change was -7.21±3.10 mm Hg in the 
TJO-002 group and -7.02±3.17 mm Hg in the BAK latanoprost 
group. Both groups showed a statistically significant decrease 
of average diurnal IOP (P<0.0001) compared with baseline, 
but there was no significant difference in the follow-up IOPs 
and IOP changes between the two groups (Table 2). 
Table 3 shows the change in the mean IOP at 9 a.m. of each 
follow-up visit after drug administration compared to baseline. 
Both groups showed a statistically significant decrease in IOP 
at each follow-up visit (P<0.0001 each) from the baseline 
IOPs, but there was no statistically significant difference in the 
follow-up IOPs between the two groups. 
Although the IOP in the TJO-002 group was less than that of 
the BAK latanoprost group at 9 a.m. at 8wk after the beginning 
of the instillation, the difference was not statistically significant 
(P=0.06). Table 4 shows diurnal IOP fluctuation from 9 a.m. to 
5 p.m. at 8 and 12wk of drug administration compared to that 
of baseline. The IOP fluctuations of the TJO-002 group were 
less than those of the BAK latanoprost group during the entire 
study period. However, the difference did not reach statistical 
Table 1 Patient demographics
Parameters TJO-002 (n=74) BAK latanoprost (n=70) P
Sex (M:F) 58:16 42:28 0.0167
Age (y) 55.93±15.02 57.96±14.56 0.4203
Body mass index (kg/m2) 24.68±3.52 24.19±2.69 0.5895
Age of glaucoma diagnosis (y) 53.92±14.98 55.59±14.70 0.5865
Duration of glaucoma (mo) 29.50±37.75 34.01±48.64 0.7811
Diabetes mellitus, n (%) 17 (22.97) 13 (18.57) 0.7564
Hypertension, n (%)  23 (31.08) 25 (35.71) 0.8934
Figure 1 Study schedule  Eligible patients were randomized to either 
the TJO-002 group or the BAK-preserved latanoprost group.
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Figure 2 Study progress diagram  FAS: Full analysis set; PPS: Per protocol set.




Baseline 12wk Change (%) Baseline 12wk Change (%)
ITT 22.87±3.12 15.77±2.78 -30.22±11.20 23.14±2.77 16.12±2.84 -29.97±11.55 <0.0001 0.7871 (-4.18, 3.17)
PP 23.04±3.22 15.84±2.87 -30.88±10.96 23.21±2.88 16.20±2.86 -30.06±11.84 <0.0001 0.5337 (-4.84, 2.93)
aSignificant difference in IOP change at week 12 of administration as compared with baseline (P<0.05 paired t-test); bDifference in IOP change 
between TJO-002 and BAK latanoprost (ANCOVA model); c95%CI from ANCOVA model. ITT: Intent-to-treat; PP: Per protocol.




IOP Change (%)a Pb IOP Change (%)a Pb
4wk
ITT 9 a.m. 15.96±2.95 -31.69±1.36 <0.0001 16.37±2.68 -30.33±1.42 <0.0001 0.4906 (-5.25, 2.53)
ITT 5 p.m.        NA NA NA
PP 9 a.m. 16.00±3.01 -31.63±1.45 <0.0001 16.41±2.63 -30.69±1.49 <0.0001 0.6500 (-5.06, 3.17)
PP 5 p.m.        NA NA NA
8wk
ITT 9 a.m. 15.57±2.50 -33.53±1.31 <0.0001 16.42±2.97 -29.96±1.37 <0.0001 0.0617 (-7.31, 0.18)
ITT 5 p.m. 15.57±2.61 -29.08±1.42 <0.0001 15.82±2.93 -28.99±1.50 <0.0001 0.9653 (-4.18, 4.00)
PP 9 a.m. 15.64±2.55 -33.80±1.41 <0.0001 16.52±3.00 -29.97±1.46 <0.0001 0.0617 (-7.84, 0.19)
PP 5 p.m. 15.55±2.67 -30.11±1.49 <0.0001 15.85±3.01 -29.30±1.54 <0.0001 0.7047 (-5.05, 3.42)
12wk
ITT 9 a.m. 15.55±2.92 -33.16±1.40 <0.0001 16.18±3.09 -31.05±1.45 <0.0001 0.2983 (-6.10, 1.88)
ITT 5 p.m. 15.98±2.98 -26.89±1.48 <0.0001 16.03±2.92 -28.13±1.56 <0.0001 0.5668 (-3.03, 5.50)
PP 9 a.m. 15.63±3.02 -33.62±1.50 <0.0001 16.26±3.09 -31.13±1.55 <0.0001 0.2508 (-6.77, 1.78)
PP 5 p.m. 16.05±3.08 -27.68±1.55 <0.0001 16.13±2.98 -28.30±1.60 <0.0001 0.7830 (-3.81, 5.04)
aAdjusted mean (%) ±SE. bSignificant difference in measurement time compared with baseline (P<0.05 paired t-test); cDifference in IOP change 
between TJO-002 and BAK latanoprost (ANCOVA model); d95%CI from ANCOVA model. ITT: Intent-to-treat; PP: Per protocol.
Preservative-free latanoprost
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significance except by 8wk after instillation (P<0.0342).  
Safety  Table 5 shows ocular and systemic AEs in both 
groups. The incidence of AEs regardless of relationship with 
the study medications was 24.66% (18/73 people, 26 cases) 
in the TJO-002 group and 25.00% (17/68, 27 cases) in the 
BAK latanoprost group; there was no statistically significant 
difference between the groups (P=0.9625). The incidence of 
“Eye disorders” in the BAK latanoprost group was 10.29% 
(7/68 people, 10 cases), and in the TJO-002 group, it was 
12.33% (9/73, 13 cases). The difference in incidence between 
the groups was not statistically significant (P=0.7035). Drug-
associated systemic adverse events other than ocular adverse 
events included nasopharyngitis (1) and cerebral infarction (1) 
in the TJO-002 group and atypical mycobacterial pneumonia 
(1), bronchiolitis (1), sinusitis (1), acute myeloid leukemia (1) 
and rash (1) in the BAK latanoprost group. However, those AE 
did not appear to be associated with the study medications.
Tolerability  Severity of pruritus, burning/stinging, blurred 
vision, sticky eye sensation, eye dryness sensation, and foreign 
body sensation were compared between the two groups at 
4-, 8-, and 12-week visits in the PP population among them, 
the severity of pruritus (12wk: P=0.0117), burning/stinging 
(4wk: P=0.0256, 8wk: P=0.0003, 12wk: P<0.0001), and 
sticky eye sensation (8wk: P=0.0010) were significantly 
different between the groups. TJO-002 showed a statistically 
significantly better tolerability than BAK latanoprost in three 
categories (Table 6). 
DISCUSSION 
In this randomized, investigator-masked multicenter trial 
in patients with POAG/OHT, the newly formulated PF 
latanoprost, TJO-002, showed similar efficacy and better 
tolerability compared with BAK latanoprost. In terms of 
efficacy, TJO-002 was non-inferior to BAK latanoprost in 
lowering IOP at all study follow-up assessment points (week 
4, 8, and 12). In terms of tolerability, TJO-002 showed 
lower incidence of pruritus, burning/stinging, and sticky 
eye sensation than BAK latanoprost for the study duration. 
There was no difference in systemic side effects between the 
two groups. TJO-002 appeared to have better efficacy and 
tolerability compared with BAK latanoprost eyedrops.
Measured IOPs were significantly reduced at all follow-up 
periods from baseline in the groups, and neither the magnitude 




Baseline 8wk Pa 12wk Pb Baseline 8wk Pa 12wk Pb
ITT 7.89±3.24 -0.21±2.94 <0.0001 -0.39±1.99 <0.0001 7.45±3.30 0.69±2.00 <0.0001 -0.01±2.20 <0.0001 0.0342 0.2812
PP 8.01±3.27 -0.17±3.05 <0.0001 -0.41±2.04 <0.0001 7.41±3.37 0.61±1.96 <0.0001 0.14±1.96 <0.0001 0.0832 0.1138
aSignificant difference in IOP change at week 8 of administration as compared with baseline (P<0.05 paired t-test); bSignificant difference in IOP 
change at week 12 of administration as compared with baseline (P<0.05 paired t-test); cDifference in diurnal IOP change at week 8 between TJO-
002 and BAK latanoprost (t-test model); dDifference in diurnal IOP change at week 12 between TJO-002 and BAK latanoprost (t-test model). 
ITT: Intent-to-treat; PP: Per protocol.
Table 5 Number of patients with ocular adverse events and drug-associated systemic adverse events
Parameters
TJO-002 (n=73) BAK latanoprost (n=68)
n (%) Events n (%) Events
Total adverse events 18 (24.66) 26 17 (25.00%) 27
Eye disorders 9 (12.33) 13 7 (10.29) 10
Dry eye 3 (4.11) 3 3 (4.41) 3
Conjunctival hyperemia 3 (4.11) 3 1 (1.47) 1
Eye pain 1 (1.37) 1 2 (2.94) 2
Foreign body sensation in eyes 2 (2.74) 2 1 (1.47) 1
Ocular hyperemia 1 (1.37) 1 1 (1.47) 1
Vision blurred 1 (1.37) 1 1 (1.47) 1
Subconjunctival hemorrhage 1 (1.37) 1 0 0
Eye pruritus 1 (1.37) 1 0 0
Punctate keratitis 0 0 1 (1.47) 1
Systemic adverse events 2 (2.74) 2 4 (5.88) 5
Nasopharyngitis 1
Cerebral infarction 1





nor the distribution of the IOP reduction at any visits were 
statistically different between the two groups. When the IOP 
measured at 9 a.m. was analyzed separately, as it approximates 
the time of maximal IOP reduction by both medications, it was 
decreased and maintained for the entire duration of the study. 
This means that TJO-002 was at least non-inferior to BAK 
latanoprost in terms of the ability to lower IOP. The reduction 
of mean IOP at 9 a.m. of the last visit compared with baseline 
was -8.13 mm Hg (33.16%) for TJO-002 and -7.43 mm Hg
(31.05%) for BAK latanoprost, which was consistent with the 
range of the optimal IOP reduction associated with latanoprost 
0.005% (approximately 28%-31%) reported previously[22-24]. 
Aspberg et al[22] reported that latanoprost was associated 
with a 28% decrease from the baseline IOP. These results 
are in agreement with the result of a study in which the IOP-
lowering efficacy of latanoprost was not dependent on the 
presence of BAK. Pellinen and Lokkila[25] demonstrated 
comparable corneal penetration of preserved and PF tafluprost 
in the aqueous humor of rabbits. Aihara et al[26] reported that 
fewer ocular surface complications without significant IOP 
changes were observed with BAK-free travoprost than with 
BAK latanoprost, with a reduced prevalence of superficial 
punctate keratitis and less hyperemia, in a long-term 12-month 
prospective study. Harasymowycz et al[23] reported that PF 
latanoprost showed the same efficacy, along with improved 
local tolerance, compared with BAK latanoprost. 
Considering the importance of adherence and the fact that 
glaucoma requires long-term treatment, local ocular tolerability 
as well as efficacy is an important factor in preserving the 
quality of life in patients with glaucoma. In this study, TJO-002 
showed better tolerability compared with BAK latanoprost, in 
terms of pruritus, burning/stinging, and sticky eye sensation. 
There are several presumed reasons for the favorable tolerability 
of TJO-002. One may be the absence of BAK. While BAK 
is a commonly used preservative in ophthalmic eye drops, 
its ocular toxicity is well known. Some studies have shown 
Table 6 Number of patients with symptoms categorized by severity level comparing the TJO-002 group and the BAK latanoprost group         n (%)
Parameters Level
TJO-002 BAK latanoprost
4wk 8wk 12wk 4wk 8wk 12wk
Pruritusa None 52 (81.25) 55 (86.36) 57 (89.39) 43 (71.67) 45 (74.19) 41 (69.35)
Mild 10 (15.63) 7 (10.61) 6 (9.09) 15 (25.00) 12 (20.97) 16 (25.81)
Moderate 1 (1.56) 2 (3.03) 1 (1.52) 0 3 (4.84) 3 (4.84)
Severe 1 (1.56) 0 0 2 (3.33) 0 0
Burning/stingingb None 48 (75.00) 53 (82.81) 52 (81.25) 29 (48.33) 30 (50.00) 25 (41.67)
Mild 13 (20.31) 8 (12.50) 11 (17.19) 21 (35.00) 22 (36.67) 23 (38.33)
Moderate 2 (3.13) 3 (4.67) 1 (1.56) 6 (10.00) 6 (10.00) 11 (18.33)
Severe 1 (1.56) 0 0 4 (6.67) 2 (3.33) 1 (1.67)
Blurred vision None 49 (76.56) 50 (78.13) 53 (82.81) 40 (66.67) 43 (71.67) 41 (68.33)
Mild 14 (21.88) 12 (18.75) 9 (14.06) 16 (26.67) 16 (26.67) 15 (25.00)
Moderate 1 (1.56) 1 (1.56) 2 (3.13) 3 (5.00) 0 3 (5.00)
Severe 0 1 (1.56) 0 1 (1.67) 1 (1.67) 1 (1.67)
Sticky eye sensationc None 56 (87.50) 60 (93.75) 57 (89.06) 47 (78.33) 45 (75.00) 45 (75.00)
Mild 7 (10.94) 2 (3.13) 6 (9.38) 13 (21.67) 14 (23.33) 14 (23.33)
Moderate 1 (1.56) 1 (1.56) 1 (1.56) 0 1 (1.67) 1 (1.67)
Severe 0 1 (1.56) 0 0 0 0
Eye dryness sensation None 49 (76.56) 50 (78.13) 51 (79.69) 44 (73.33) 37 (61.67) 42 (70.00)
Mild 12 (18.75) 10 (15.63) 11 (17.19) 12 (20.00) 20 (33.33) 15 (25.00)
Moderate 1 (1.56) 4 (6.25) 2 (3.13) 4 (6.67) 3 (5.00) 3 (5.00)
Severe 2 (3.13) 0 0 0 0 0
Foreign body sensation None 52 (81. 25) 46 (71.88) 48 (75.00) 41 (68.33) 40 (66.67) 41 (68.33)
Mild 9 (14.06) 17 (26.56) 14 (21.88) 14 (23.33) 15 (8.33) 14 (23.33)
Moderate 1 (1.56) 1 (1.56) 2 (3.13) 4 (6.67) 5 (8.33) 3 (5.00)
Severe 2 (3.13) 0 0 1 (1.67) 0 2 (3.33)
aStatistical difference (P<0.05) of symptom severity change at 12wk (Fisher’s exact test). bStatistical difference (P<0.05) of symptom severity 
change at 4, 8, and 12wk (Fisher’s exact test). cStatistical difference (P<0.05) of symptom severity change at 8wk (Fisher’s exact test).
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ocular surface damage, including inflammatory and toxic 
effects, associated with BAK[14,27-28]. Martinez-de-la-Casa et 
al[29] reported that the preservative appeared to have an impact 
on tear cytokine levels. Latanoprost with BAK increased the 
levels of interleukin, basic fibroblast growth factor, platelet-
derived growth factor, and tumor necrosis factor-α in tear 
film. Baudouin et al[28] also suggested that BAK in topical eye 
drops induces tear film instability, conjunctival inflammation, 
subconjunctival fibrosis, epithelial apoptosis, and corneal 
surface impairment. Long-term use of BAK could lead to 
apoptosis of conjunctival cells and chronic conjunctival 
inflammation[30]. Furthermore, Desbenoit et al[31] reported 
that BAK was found in the iris, lens capsule, and trabecular 
meshwork tissue of rabbits after topical exposure, thus 
suggesting the penetration of BAK into deep ocular structures. 
Pisella et al[32] demonstrated that removal of preservative from 
timolol ophthalmic solution was associated with improvement 
of corneal epithelial barrier function, prevention of ocular 
surface inflammation, and reduction of complaints. Yang 
et al[33] suggested that topical latanoprost treatment itself 
could induce dry eye via inflammation. They reported the 
effects of latanoprost in mice: it decreased tear production, 
induced conjunctival goblet cell loss, disrupted the corneal 
epithelial barrier, and promoted cell apoptosis in the ocular 
surface. Therefore, latanoprost itself may cause ocular surface 
problems, and BAK can further aggravate that problem. The 
new BAK-free formulation of latanoprost in this study, TJO-002, 
appeared to minimize the discomfort by eliminating BAK toxicity. 
Another reason may be the ocular tissue-friendly composition 
of TJO-002, which includes carbomer and sorbitol as the 
excipient. Carbomer has been widely used for artificial tears[30]. 
Carbomers are anionic polymers and strongly interact with 
anionic mucin[34]. This mucoadhesive interaction causes 
carbomer-based formulations to bind with the mucin layer to 
prolong adhesion[35]. Reports have demonstrated that the ocular 
retention time of carbomer gel was significantly longer than 
that of other low-viscosity eye drops[36-37]. In a previous study, 
when compared to sodium hyaluronate, carbomer showed 
equivalent therapeutic effects on symptom severity in moderate 
dry eye[37]. The properties of carbomer seem to play a role in 
reducing ocular AEs. Furthermore, due to the characteristics 
of the carbomer, latanoprost may stay on the surface of the 
eye longer, possibly resulting in a better IOP reduction. The 
IOP at 9 a.m. after 8wk in the TJO-002 group was lower 
than that in the BAK latanoprost group. Sorbitol is used to 
enhance the stability of the topical composition in TJO-002. 
In a 4-week test of stability under severe conditions (55°C, 
relative humidity 75%), the main ingredient, latanoprost, 
was maintained without loss. This result showed that the 
latanoprost preparation containing sorbitol was kept more 
stable than the preparation without sorbitol (data not shown 
here). Sorbitol appeared to maintain the stability of TJO-002 
at room temperature for 3y. In addition, the appropriate pH for 
activation and maintenance of TJO-002 is pH 7.0-7.3, at which 
TJO-002 is neutral, while that of BAK-preserved latanoprost 
used in this study (Xalatan®, Pfizer Inc., Belgium NV Puurs, 
Belgium) is pH 5.5. This may be one of the reasons why there is 
less tingling sensation with TJO-002 than with BAK latanoprost. 
Gonnering et al[38] showed that the optimal pH range to prevent 
corneal damage is 6.5 to 8.5, which includes the pH of lacrimal 
fluid (approximately pH 7.4). Although corneas perfused at 
pH 5.5 showed changes in endothelial morphology, those 
perfused at pH values of 7.0, 8.0, and 8.5 maintained normal 
endothelial morphology[38]. While conjunctival hyperemia was 
more common in TJO-002 (3 vs 1). Considering the absence 
of stimulation by BAK, it was expected to appear less, but the 
opposite result was obtained. The exact reason for this is not 
known. In our opinion, the carbomer contained in TJO-002 may 
be the result of prolonging the hyperemia effect of latanoprost 
by causing latanoprost to stay in the conjunctival sac for a long 
time. Severe foreign body sensation was shown in 2 cases of 
TJO-002 at 4wk after instillation and were lost over time, but 
in BAK latanoprost, severe case was shown at 12wk. Further 
study is needed.
Despite various efforts, this study has several limitations. 
First, there was no objective examination for ocular surface 
evaluation, such as tear film break-up testing and corneal/
conjunctival staining evaluations. Second, the study was 
performed using data from one ethnic group; thus, results 
may not be applicable to other ethnic groups. Third, we did 
not evaluate all adverse effects of prostaglandin analogue 
(e.g., lid pigmentation, deepening of upper eyelid sulcus, and 
growth of eyelashes) due to the relatively short follow-up 
duration. Fourth, other ingredients in addition to BAK may 
have been involved, but comparisons were not made. Since 
not all of the component of two drugs are the same except for 
BAK, all other ingredients in the drug may be involved. Fifth, 
our study conducted a relatively short follow-up duration, 
12wk. Considering that responses may vary from person to 
person, the duration of the study may not be appropriate. 
Further longterm study is needed. Sixth, we did not measure 
the 24-hour IOP variation, but only examined IOP twice in a 
day to estimate a certain daily change. However, despite the 
above limitations, we consider that we sufficiently evaluated 
and compared TJO-002, PF latanoprost, with conventional 
latanoprost containing preservative in terms of IOP reduction 
and ocular surface adverse effects. Finally, compared to 
previous studies, the subjects in our study are more male and 
have a relatively young average age. Other similar studies 
show that the average age is mostly over 60, with similar sex 
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ratios or more female than male[39-42]. However, since our study 
is a multicenter study, and we have not tried to control the 
sex ratio of patients, it is not known why this structure was 
established. Considering the possible reasons, our study was 
performed in tertiary hospital and general hospitals. These 
hospitals in Korea are located in large cities, and residents of 
large cities and office workers around them participated in 
the study, so it seems that there were relatively more males 
and younger people than other studies. In addition, male have 
a higher prevalence of glaucoma than female in Korea[43]. It 
will be difficult to put our study on the same line with other 
existing studies and compare it, but it will be a good reference 
considering age and gender.
In conclusion, PF latanoprost generic, TJO-002, offers a useful 
alternative to the available prostaglandin analogues containing 
BAK for the treatment of POAG/OHT and is likely to be 
associated with fewer ocular surface problems, without any 
reduction in efficacy. On the basis of our result, PF-latanoprost 
could be considered as an alternative to conventional 
latanoprost, especially in patients suffering from pre-existing 
or concomitant ocular surface diseases. In the future, it is also 
of interest to study the comparison of the difference between 
efficacy and safety with and without preservatives in three 
different prostaglandin analogues in relation to the surface eye 
effect of PF.
ACKNOWLEDGEMENTS
Foundation: Supported by Taejoon Pharmaceutical.
Conflicts of Interest: Kim JM, None; Sung KR, None; 
Lee JW, None; Kyung H, None; Rho S, None; Kim CY, 
None.
REFERENCES 
1 Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global 
prevalence of glaucoma and projections of glaucoma burden through 
2040: a systematic review and meta-analysis. Ophthalmology 
2014;121(11):2081-2090. 
2 Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-
angle glaucoma (UKGTS): a randomised, multicentre, placebo-
controlled trial. Lancet 2015;385(9975):1295-1304. 
3 Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein 
M, Early Manifest Glaucoma Trial Group. Reduction of intraocular 
pressure and glaucoma progression: results from the Early Manifest 
Glaucoma Trial. Arch Ophthalmol 2002;120(10):1268-1279. 
4 Armaly MF, Krueger DE, Maunder L, Becker B, Hetherington J Jr, 
Kolker AE, Levene RZ, Maumenee AE, Pollack IP, Shaffer RN. 
Biostatistical analysis of the collaborative glaucoma study. I. Summary 
report of the risk factors for glaucomatous visual-field defects. Arch 
Ophthalmol 1980;98(12):2163-2171. 
5 Wilson R, Walker AM, Dueker DK, Crick RP. Risk factors for rate 
of progression of glaucomatous visual field loss: a computer-based 
analysis. Arch Ophthalmol 1982;100(5):737-741. 
6 Han YS, Ha A, Kim YK, Jeoung JW, Park KH. Normal-tension 
glaucoma management: a survey of glaucoma sub-specialists in Korea. 
Korean J Ophthalmol 2020;34(6):425-431. 
7 Shukla AG, De Moraes CG, Cioffi GA, Girkin CA, Weinreb RN, 
Zangwill LM, Liebmann JM. The relationship between intraocular 
pressure and rates of central versus peripheral visual field progression. 
J Glaucoma 2020;29(6):435-440. 
8 Stewart WC, Kolker AE, Sharpe ED, Day DG, Holmes KT, Leech JN, 
Johnson M, Cantrell JB. Factors associated with long-term progression 
or stability in primary open-angle glaucoma. Am J Ophthalmol 
2000;130(3):274-279. 
9 Mansouri K, Tanna AP, De Moraes CG, Camp AS, Weinreb RN. Review 
of the measurement and management of 24-hour intraocular pressure in 
patients with glaucoma. Surv Ophthalmol 2020;65(2):171-186. 
10 Digiuni M, Fogagnolo P, Rossetti L. A review of the use of 
latanoprost for glaucoma since its launch. Expert Opin Pharmacother 
2012;13(5):723-745. 
11 Alm A. Latanoprost in the treatment of glaucoma. Clin Ophthalmol 
2014;8:1967-1985. 
12 Orme M, Collins S, Dakin H, Kelly S, Loftus J. Mixed treatment 
comparison and meta-regression of the efficacy and safety of 
prostaglandin analogues and comparators for primary open-angle 
glaucoma and ocular hypertension. Curr Med Res Opin 2010;26(3): 
511-528. 
13 Tong L, Matsuura E, Takahashi M, Nagano T, Kawazu K. Effects of 
anti-glaucoma prostaglandin ophthalmic solutions on cultured human 
corneal epithelial cells. Curr Eye Res 2019;44(8):856-862. 
14 Kim JH, Kim EJ, Kim YH, Kim YI, Lee SH, Jung JC, Lee KW, Park 
YJ. In vivo effects of preservative-free and preserved prostaglandin 
analogs: mouse ocular surface study. Korean J Ophthalmol 2015;29(4): 
270-279. 
15 Su CC, Lee YC, Lee PRC. Assessment of ocular surface disease in 
glaucoma patients with benzalkonium chloride-preserved latanoprost 
eye drops: a short-term longitudinal study. Graefes Arch Clin Exp 
Ophthalmol 2021;259(5):1243-1251. 
16 Mohammed I, Kulkarni B, Faraj LA, Abbas A, Dua HS, King AJ. 
Profiling ocular surface responses to preserved and non-preserved 
topical glaucoma medications: a 2-year randomized evaluation study. 
Clin Exp Ophthalmol 2020;48(7):973-982. 
17 EMEA public statement on antimicrobial preservatives in ophthalmic 




18 Allergan. Safety and efficacy of bimatoprost compared with latanoprost 
in patients with glaucoma or ocular hypertension. Bethesda, Md: 
ClinicalTrials.gov; 2007. Identifier: NCT00541242. 
19 Aptel F, Pfeiffer N, Schmickler S, Clarke J, Lavín-Dapena C, Moreno-
Montañés J, Żarnowski T, Csutak A, Jugaste T, Volksone L, Astakhov 
YS, Coupier L, Nordmann JP, Stalmans I; T2347 Study Group. 
Preservative-free latanoprost
1547
Int J Ophthalmol,    Vol. 14,   No. 10,  Oct.18,  2021        www.ijo.cn
Tel: 8629-82245172     8629-82210956      Email: ijopress@163.com
Noninferiority of preservative-free versus BAK-preserved latanoprost-
timolol fixed combination eye drops in patients with open-angle 
glaucoma or ocular hypertension. J Glaucoma 2019;28(6):498-506.
20 Diestelhorst M, Larsson LI, European-Canadian Latanoprost Fixed 
Combination Study Group. A 12-week, randomized, double-masked, 
multicenter study of the fixed combination of latanoprost and timolol 
in the evening versus the individual components. Ophthalmology 
2006;113(1):70-76. 
21 Cox JA, Mollan SP, Bankart J, Robinson R. Efficacy of antiglaucoma 
fixed combination therapy versus unfixed components in reducing 
intraocular pressure: a systematic review. Br J Ophthalmol 2008;92(6): 
729-734. 
22 Aspberg J, Heijl A, Jóhannesson G, Lindén C, Andersson-Geimer S, 
Bengtsson B. Intraocular pressure lowering effect of latanoprost as 
first-line treatment for glaucoma. J Glaucoma 2018;27(11):976-980. 
23 Harasymowycz P, Hutnik C, Rouland JF, Negrete FJM, Economou 
MA, Denis P, Baudouin C. Preserved versus preservative-free 
latanoprost for the treatment of glaucoma and ocular hypertension: a 
post hoc pooled analysis. Adv Ther 2021;38(6):3019-3031. 
24 Misiuk-Hojlo M, Pomorska M, Mulak M, et al. The RELIEF study: 
tolerability and efficacy of preservative-free latanoprost in the 
treatment of glaucoma or ocular hypertension. Eur J Ophthalmol 
2019;29(2):210-215.
25 Pellinen P, Lokkila J. Corneal penetration into rabbit aqueous humor 
is comparable between preserved and preservative-free tafluprost. 
Ophthalmic Res 2009;41(2):118-122. 
26 Aihara M, Otani S, Kozaki J, Unoki K, Takeuchi M, Minami K, 
Miyata K. Long-term effect of BAK-free travoprost on ocular surface 
and intraocular pressure in glaucoma patients after transition from 
latanoprost. J Glaucoma 2012;21(1):60-64. 
27 Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms 
and signs with preserved and preservative free glaucoma medication. 
Br J Ophthalmol 2002;86(4):418-423. 
28 Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. 
Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin 
Eye Res 2010;29(4):312-334. 
29 Martinez-de-la-Casa JM, Perez-Bartolome F, Urcelay E, Santiago 
JL, Moreno-Montanes J, Arriola-Villalobos P, Benitez-Del-Castillo 
JM, Garcia-Feijoo J. Tear cytokine profile of glaucoma patients 
treated with preservative-free or preserved latanoprost. Ocul Surf 
2017;15(4):723-729. 
30 Boimer C, Birt CM. Preservative exposure and surgical outcomes in 
glaucoma patients: the PESO study. J Glaucoma 2013;22(9):730-735. 
31 Desbenoit N, Schmitz-Afonso I, Baudouin C, Laprévote O, Touboul 
D, Brignole-Baudouin F, Brunelle A. Localisation and quantification 
of benzalkonium chloride in eye tissue by TOF-SIMS imaging and 
liquid chromatography mass spectrometry. Anal Bioanal Chem 
2013;405(12):4039-4049. 
32 Pisella PJ, Debbasch C, Hamard P, Creuzot-Garcher C, Rat P, Brignole 
F, Baudouin C. Conjunctival proinflammatory and proapoptotic effects 
of latanoprost and preserved and unpreserved timolol: an ex vivo and in 
vitro study. Invest Ophthalmol Vis Sci 2004;45(5):1360-1368. 
33 Yang YR, Huang CH, Lin X, Wu Y, Ouyang WJ, Tang LY, Ye SH, 
Wang YH, Li W, Zhang XB, Liu ZG. 0.005% preservative-free 
latanoprost induces dry eye-like ocular surface damage via promotion 
of inflammation in mice. Invest Ophthalmol Vis Sci 2018;59(8):3375-3384. 
34 Wilson CG, Zhu YP, Frier M, Rao LS, Gilchrist P, Perkins AC. Ocular 
contact time of a carbomer gel (GelTears) in humans. Br J Ophthalmol 
1998;82(10):1131-1134. 
35 Marquardt R, Christ T. Corneal contact time of artificial tear solutions. 
Klin Monbl Augenheilkd 1986;189(3):254-257. 
36 Xiao Q, Hu YH, Chen F, Chen XM. A comparative assessment of 
the efficacy of carbomer gel and carboxymethyl cellulose containing 
artificial tears in dry eyes. J Huazhong Univ Sci Technolog Med Sci 
2008;28(5):592-595.
37 Johnson ME, Murphy PJ, Boulton M. Carbomer and sodium 
hyaluronate eyedrops for moderate dry eye treatment. Optom Vis Sci 
2008;85(8):750-757. 
38 Gonnering R, Edelhauser HF, van Horn DL, Durant W. The pH 
tolerance of rabbit and human corneal endothelium. Invest Ophthalmol 
Vis Sci 1979;18(4):373-390. 
39 Asrani S, Robin AL, Serle JB, Lewis RA, Usner DW, Kopczynski CC, 
Heah T, MERCURY- Study Group. Netarsudil/latanoprost fixed-dose 
combination for elevated intraocular pressure: three-month data from a 
randomized phase 3 trial. Am J Ophthalmol 2019;207:248-257. 
40 Nguyen QH, McMenemy MG, Realini T, Whitson JT, Goode SM. 
Phase 3 randomized 3-month trial with an ongoing 3-month safety 
extension of fixed-combination brinzolamide 1%/brimonidine 0.2%. J 
Ocul Pharmacol Ther 2013;29(3):290-297. 
41 Yamamoto T, Ikegami T, Ishikawa Y, Kikuchi S, OPC-EL & Study 
Groups. Randomized, controlled, phase 3 trials of carteolol/latanoprost 
fixed combination in primary open-angle glaucoma or ocular 
hypertension. Am J Ophthalmol 2016;171:35-46. 
42 Aihara M, Lu FH, Kawata H, Iwata A, Odani-Kawabata N, Shams 
NK. Omidenepag isopropyl versus latanoprost in primary open-angle 
glaucoma and ocular hypertension: the phase 3 AYAME study. Am J 
Ophthalmol 2020;220:53-63. 
43 Kim KE, Kim MJ, Park KH, Jeoung JW, Kim SH, Kim CY, Kang SW, 
Epidemiologic Survey Committee of the Korean Ophthalmological 
Society. Prevalence, awareness, and risk factors of primary open-angle 
glaucoma: Korea national health and nutrition examination survey 
2008-2011. Ophthalmology 2016;123(3):532-541. 
